MitoCareX Bio
Novel Therapies for Hard-to-treat Resistant Cancers
Company Overview
Snapshot
Founded in February 2022 by Alon Silberman, MitoCareX Bio operates with 1–10 employees. The company was acquired by N2OFF in March 2025, marking a significant milestone in its development.
Business overview
MitoCareX Bio is a drug discovery company focused on developing novel therapies for hard-to-treat lung cancer by targeting mitochondrial transporters (SLC25 protein family). The company utilizes its proprietary MITOLINE algorithm and advanced computational capabilities to generate reliable 3D models for mitochondrial proteins, facilitating the discovery of new potential drugs. Its cloud-based computational platform efficiently screens numerous small molecules against these 3D models to identify hit candidates for preclinical development. MitoCareX Bio operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Strategic signal
In January 2025, MitoCareX Bio expanded its research to pancreatic cancer following initial in-vitro positive results. This strategic expansion indicates the company's potential to leverage its drug discovery platform beyond its initial focus on lung cancer, suggesting broader applicability and market opportunities for its novel therapeutic approaches.
Company Intelligence Q&A
- What is MitoCareX Bio's primary focus in drug discovery?
- MitoCareX Bio primarily focuses on the discovery and development of novel therapies for hard-to-treat lung cancer by targeting mitochondrial transporters (SLC25 protein family).
- When was MitoCareX Bio acquired and by whom?
- MitoCareX Bio was acquired by N2OFF in March 2025.
- What proprietary technology does MitoCareX Bio use for drug discovery?
- MitoCareX Bio utilizes its MITOLINE algorithm and other advanced computational capabilities to generate reliable 3D models for mitochondrial proteins, which is crucial for computer-aided drug design.
- Has MitoCareX Bio expanded its research beyond lung cancer?
- Yes, in January 2025, MitoCareX Bio expanded its research to pancreatic cancer following initial in-vitro positive results.
- Who is the founder of MitoCareX Bio?
- Alon Silberman is the founder and CSO of MitoCareX Bio.